| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Medicine [M. L. D., G. M., A. E. M., W. C., R. B. L., M. A. C.] and Surgery [R. M.], University of Washington, Seattle, Washington 98195; Department of Otolaryngology, Northwestern University, Chicago, Illinois, 60611 [E. C.]; and Friedrich Miescher-Institut [B. G., M. J.] and Ciba-Geigy Limited [N. L., E. M.], Basel, Switzerland
2 A Berlex Oncology Foundation Fellow. To whom requests for reprints should be addressed.
The HER-2/neu protooncogene is amplified and overexpressed in 20–40% of invasive breast cancers. HER-2/neu protein overexpression is associated with aggressive disease and is an independent predictor of poor prognosis in several subsets of patients. The protein may also be related to cancer formation, with overexpression being detectable in 50–60% of ductal carcinomas in situ. It has been suggested that it might be possible to develop specific T-cell therapy directed against proteins involved in malignant transformation. One question is whether normal proteins that are overexpressed are appropriate targets for therapeutic immune attack. This report demonstrates that some patients with HER-2/neu-positive breast cancers have both existent CD4+ helper/inducer T-cell immunity and antibody-mediated immunity to HER-2/neu protein. Initial studies performed on 20 premenopausal breast cancer patients identified antibodies to HER-2/neu in 11 individuals. Similar antibody responses have been found in some normal individuals. The patient with the greatest antibody response was studied in detail. In addition to a humoral immune response this patient had evidence of a significant proliferative T-cell response to the HER-2/neu protein and peptides. Similar T-cell responses have been detected in additional patients. It has been assumed that patients would be immunologically tolerant to HER-2/neu as a self-protein and that immunity might be difficult to generate. If immunity could be generated, the result might be destructive autoimmunity. The current data support the notion that HER-2/neu-specific immunity might be used in therapy without destroying normal tissue but also raises questions as to the role of existent immunity in immune surveillance and cancer progression.
1 This work was supported by Grants T32 CA09515, R01 CA54561, and R37 CA30558, National Cancer Institute, NIH, Department of Health and Human Services.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 9/10/93. Accepted 11/16/93.
This article has been cited by other articles:
|
|
 |
|
  A. Sloots, C. Mastini, F. Rohrbach, R. Weth, C. Curcio, U. Burkhardt, E. Jager, G. Forni, F. Cavallo, and W. S. Wels DNA Vaccines Targeting Tumor Antigens to B7 Molecules on Antigen-Presenting Cells Induce Protective Antitumor Immunity and Delay Onset of HER-2/Neu-Driven Mammary Carcinoma Clin. Cancer Res., November 1, 2008; 14(21): 6933 - 6943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Barve, J. Bender, N. Senzer, C. Cunningham, F. A. Greco, D. McCune, R. Steis, H. Khong, D. Richards, J. Stephenson, et al. Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non-Small-Cell Lung Cancer J. Clin. Oncol., September 20, 2008; 26(27): 4418 - 4425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Worschech, M. Kmieciak, K. L. Knutson, H. D. Bear, A. A. Szalay, E. Wang, F. M. Marincola, and M. H. Manjili Signatures Associated with Rejection or Recurrence in HER-2/neu-Positive Mammary Tumors Cancer Res., April 1, 2008; 68(7): 2436 - 2446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Park, M. Terabe, J. C. Steel, G. Forni, Y. Sakai, J. C. Morris, and J. A. Berzofsky Therapy of Advanced Established Murine Breast Cancer with a Recombinant Adenoviral ErbB-2/neu Vaccine Cancer Res., March 15, 2008; 68(6): 1979 - 1987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Monu and A. B. Frey Suppression of Proximal T Cell Receptor Signaling and Lytic Function in CD8+ Tumor-Infiltrating T Cells Cancer Res., December 1, 2007; 67(23): 11447 - 11454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-S. Lin, H. S. Talwar, A. L. Tarca, A. Ionan, M. Chatterjee, B. Ye, J. Wojciechowski, S. Mohapatra, M. D. Basson, G. H. Yoo, et al. Autoantibody Approach for Serum-Based Detection of Head and Neck Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2396 - 2405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Park, M. E. Melisko, L. J. Esserman, L. A. Jones, J. B. Wollan, and R. Sims Treatment With Autologous Antigen-Presenting Cells Activated With the HER-2 Based Antigen Lapuleucel-T: Results of a Phase I Study in Immunologic and Clinical Activity in HER-2 Overexpressing Breast Cancer J. Clin. Oncol., August 20, 2007; 25(24): 3680 - 3687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-J. Ko, Y.-J. Kim, Y.-S. Kim, W.-S. Chang, S.-Y. Ko, S.-Y. Chang, S. Sakaguchi, and C.-Y. Kang A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model Cancer Res., August 1, 2007; 67(15): 7477 - 7486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Scardino, M. Alimandi, P. Correale, S. G. Smith, R. Bei, H. Firat, M. G. Cusi, O. Faure, S. Graf-Dubois, G. Cencioni, et al. A Polyepitope DNA Vaccine Targeted to Her-2/ErbB-2 Elicits a Broad Range of Human and Murine CTL Effectors to Protect against Tumor Challenge Cancer Res., July 15, 2007; 67(14): 7028 - 7036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Allen, J. T. Garrett, S. V. Rawale, A. L. Jones, G. Phillips, G. Forni, J. C. Morris, R. G. Oshima, and P. T. P. Kaumaya Peptide Vaccines of the HER-2/neu Dimerization Loop Are Effective in Inhibiting Mammary Tumor Growth In Vivo J. Immunol., July 1, 2007; 179(1): 472 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Casiano, M. Mediavilla-Varela, and E. M. Tan Tumor-associated Antigen Arrays for the Serological Diagnosis of Cancer Mol. Cell. Proteomics, October 1, 2006; 5(10): 1745 - 1759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Knutson, C. J. Krco, C. L. Erskine, K. Goodman, L. E. Kelemen, P. J. Wettstein, P. S. Low, L. C. Hartmann, and K. R. Kalli T-Cell Immunity to the Folate Receptor Alpha Is Prevalent in Women With Breast or Ovarian Cancer J. Clin. Oncol., September 10, 2006; 24(26): 4254 - 4261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ambrosino, M. Spadaro, M. Iezzi, C. Curcio, G. Forni, P. Musiani, W.-Z. Wei, and F. Cavallo Immunosurveillance of erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res., August 1, 2006; 66(15): 7734 - 7740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Knutson, Y. Dang, H. Lu, J. Lukas, B. Almand, E. Gad, E. Azeke, and M. L. Disis IL-2 Immunotoxin Therapy Modulates Tumor-Associated Regulatory T Cells and Leads to Lasting Immune-Mediated Rejection of Breast Cancers in neu-Transgenic Mice J. Immunol., July 1, 2006; 177(1): 84 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Chatterjee, S. Mohapatra, A. Ionan, G. Bawa, R. Ali-Fehmi, X. Wang, J. Nowak, B. Ye, F. A. Nahhas, K. Lu, et al. Diagnostic Markers of Ovarian Cancer by High-Throughput Antigen Cloning and Detection on Arrays Cancer Res., January 15, 2006; 66(2): 1181 - 1190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. T. Viehl, M. Becker-Hapak, J. S. Lewis, Y. Tanaka, U. K. Liyanage, D. C. Linehan, T. J. Eberlein, and P. S. Goedegebuure A Tat Fusion Protein-Based Tumor Vaccine for Breast Cancer Ann. Surg. Oncol., July 1, 2005; 12(7): 517 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Rohrbach, R. Weth, M. Kursar, A. Sloots, H.-W. Mittrucker, and W. S. Wels Targeted Delivery of the ErbB2/HER2 Tumor Antigen to Professional APCs Results in Effective Antitumor Immunity J. Immunol., May 1, 2005; 174(9): 5481 - 5489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L A Emens, R T Reilly, and E M Jaffee Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity Endocr. Relat. Cancer, March 1, 2005; 12(1): 1 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Jiang, W. Liu, H. Qu, L. Meng, S. Song, T. Ouyang, and C. Shou A Novel Peptide Isolated from a Phage Display Peptide Library with Trastuzumab Can Mimic Antigen Epitope of HER-2 J. Biol. Chem., February 11, 2005; 280(6): 4656 - 4662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Pupa, M. Iezzi, E. Di Carlo, A. Invernizzi, F. Cavallo, R. Meazza, A. Comes, S. Ferrini, P. Musiani, and S. Menard Inhibition of Mammary Carcinoma Development in HER-2/neu Transgenic Mice through Induction of Autoimmunity by Xenogeneic DNA Vaccination Cancer Res., February 1, 2005; 65(3): 1071 - 1078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Montgomery, E. Makary, K. Schiffman, V. Goodell, and M. L. Disis Endogenous Anti-HER2 Antibodies Block HER2 Phosphorylation and Signaling through Extracellular Signal-Regulated Kinase Cancer Res., January 15, 2005; 65(2): 650 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Takeuchi, S.-i. Hiraoka, X.-Y. Zhou, M. Nagafuku, S. Ono, T. Tsujimura, M. Nakazawa, Y. Yura, T. Hamaoka, and H. Fujiwara Anti-HER-2/neu Immune Responses Are Induced before the Development of Clinical Tumors but Declined following Tumorigenesis in HER-2/neu Transgenic Mice Cancer Res., October 15, 2004; 64(20): 7588 - 7595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Bishop, D. H. Fowler, D. Marchigiani, K. Castro, C. Kasten-Sportes, S. M. Steinberg, J. C. Gea-Banacloche, R. Dean, C. K. Chow, C. Carter, et al. Allogeneic Lymphocytes Induce Tumor Regression of Advanced Metastatic Breast Cancer J. Clin. Oncol., October 1, 2004; 22(19): 3886 - 3892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Rakhmilevich, A. T. Hooper, D. J. Hicklin, and P. M. Sondel Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody Mol. Cancer Ther., August 1, 2004; 3(8): 969 - 976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Cui, G. Jin, T. Gao, T. Sun, F. Tian, G. G. Estrada, H. Gao, and A. Sarai Characterization of BRCAA1 and Its Novel Antigen Epitope Identification Cancer Epidemiol. Biomarkers Prev., July 1, 2004; 13(7): 1136 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Riemer, M. Klinger, S. Wagner, A. Bernhaus, L. Mazzucchelli, H. Pehamberger, O. Scheiner, C. C. Zielinski, and E. Jensen-Jarolim Generation of Peptide Mimics of the Epitope Recognized by Trastuzumab on the Oncogenic Protein Her-2/neu J. Immunol., July 1, 2004; 173(1): 394 - 401. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Disis, K. Schiffman, K. Guthrie, L. G. Salazar, K. L. Knutson, V. Goodell, C. dela Rosa, and M. A. Cheever Effect of Dose on Immune Response in Patients Vaccinated With an HER-2/neu Intracellular Domain Protein--Based Vaccine J. Clin. Oncol., May 15, 2004; 22(10): 1916 - 1925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Piechocki, Y.-S. Ho, S. Pilon, and W.-Z. Wei Human ErbB-2 (Her-2) Transgenic Mice: A Model System for Testing Her-2 Based Vaccines J. Immunol., December 1, 2003; 171(11): 5787 - 5794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. G. Salazar, J. Fikes, S. Southwood, G. Ishioka, K. L. Knutson, T. A. Gooley, K. Schiffman, and M. L. Disis Immunization of Cancer Patients with HER-2/neu-Derived Peptides Demonstrating High-Affinity Binding to Multiple Class II Alleles Clin. Cancer Res., November 15, 2003; 9(15): 5559 - 5565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Rentzsch, S. Kayser, S. Stumm, I. Watermann, S. Walter, S. Stevanovic, D. Wallwiener, and B. Guckel Evaluation of Pre-existent Immunity in Patients with Primary Breast Cancer: Molecular and Cellular Assays to Quantify Antigen-Specific T Lymphocytes in Peripheral Blood Mononuclear Cells Clin. Cancer Res., October 1, 2003; 9(12): 4376 - 4386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Wolpoe, E. R. Lutz, A. M. Ercolini, S. Murata, S. E. Ivie, E. S. Garrett, L. A. Emens, E. M. Jaffee, and R. T. Reilly HER-2/neu-Specific Monoclonal Antibodies Collaborate with HER-2/neu-Targeted Granulocyte Macrophage Colony-Stimulating Factor Secreting Whole Cell Vaccination to Augment CD8+ T Cell Effector Function and Tumor-Free Survival in Her-2/neu-Transgenic Mice J. Immunol., August 15, 2003; 171(4): 2161 - 2169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. Ko, K. Kawano, J. L. Murray, M. L. Disis, C. L. Efferson, H. M. Kuerer, G. E. Peoples, and C. G. Ioannides Clinical Studies of Vaccines Targeting Breast Cancer Clin. Cancer Res., August 1, 2003; 9(9): 3222 - 3234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. K. Dakappagari, J. Pyles, R. Parihar, W. E. Carson, D. C. Young, and P. T. P. Kaumaya A Chimeric Multi-Human Epidermal Growth Factor Receptor-2 B Cell Epitope Peptide Vaccine Mediates Superior Antitumor Responses J. Immunol., April 15, 2003; 170(8): 4242 - 4253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Pilon, C. Kelly, and W.-Z. Wei Broadening of Epitope Recognition During Immune Rejection of ErbB-2-Positive Tumor Prevents Growth of ErbB-2-Negative Tumor J. Immunol., February 1, 2003; 170(3): 1202 - 1208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Nahta, G. N. Hortobagyi, and F. J. Esteva Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention Oncologist, February 1, 2003; 8(1): 5 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. D. Davis, M. Jefford, P. Parente, and J. Cebon Rational approaches to human cancer immunotherapy J. Leukoc. Biol., January 1, 2003; 73(1): 3 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Murray, M. E. Gillogly, D. Przepiorka, H. Brewer, N. K. Ibrahim, D. J. Booser, G. N. Hortobagyi, A. P. Kudelka, K. H. Grabstein, M. A. Cheever, et al. Toxicity, Immunogenicity, and Induction of E75-specific Tumor-lytic CTLs by HER-2 Peptide E75 (369-377) Combined with Granulocyte Macrophage Colony-stimulating Factor in HLA-A2+ Patients with Metastatic Breast and Ovarian Cancer Clin. Cancer Res., November 1, 2002; 8(11): 3407 - 3418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Scheffold, M. Kornacker, Y. C. Scheffold, C. H. Contag, and R. S. Negrin Visualization of Effective Tumor Targeting by CD8+ Natural Killer T Cells Redirected with Bispecific Antibody F(ab')2HER2xCD3 Cancer Res., October 15, 2002; 62(20): 5785 - 5791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Scanlan, S. Welt, C. M. Gordon, Y.-T. Chen, A. O. Gure, E. Stockert, A. A. Jungbluth, G. Ritter, D. Jager, E. Jager, et al. Cancer-related Serological Recognition of Human Colon Cancer: Identification of Potential Diagnostic and Immunotherapeutic Targets Cancer Res., July 15, 2002; 62(14): 4041 - 4047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Disis, T. A. Gooley, K. Rinn, D. Davis, M. Piepkorn, M. A. Cheever, K. L. Knutson, and K. Schiffman Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide-Based Vaccines J. Clin. Oncol., June 1, 2002; 20(11): 2624 - 2632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. zum Buschenfelde, C. Hermann, B. Schmidt, C. Peschel, and H. Bernhard Antihuman Epidermal Growth Factor Receptor 2 (HER2) Monoclonal Antibody Trastuzumab Enhances Cytolytic Activity of Class I-restricted HER2-specific T Lymphocytes Against HER2-overexpressing Tumor Cells Cancer Res., April 1, 2002; 62(8): 2244 - 2247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Pilon, M. P. Piechocki, and W.-Z. Wei Vaccination with Cytoplasmic ErbB-2 DNA Protects Mice from Mammary Tumor Growth Without Anti-ErbB-2 Antibody J. Immunol., September 15, 2001; 167(6): 3201 - 3206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Piechocki, S. A. Pilon, and W.-Z. Wei Complementary Antitumor Immunity Induced by Plasmid DNA Encoding Secreted and Cytoplasmic Human ErbB-2 J. Immunol., September 15, 2001; 167(6): 3367 - 3374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Meyer zum Buschenfelde, J. Metzger, C. Hermann, N. Nicklisch, C. Peschel, and H. Bernhard The Generation of Both T Killer and Th Cell Clones Specific for the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells J. Immunol., August 1, 2001; 167(3): 1712 - 1719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. L. Yip, G. Smith, J. Koch, S. Dubel, and R. L. Ward Identification of Epitope Regions Recognized by Tumor Inhibitory and Stimulatory Anti-ErbB-2 Monoclonal Antibodies: Implications for Vaccine Design J. Immunol., April 15, 2001; 166(8): 5271 - 5278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Jäger, E. Stockert, A. O. Güre, M. J. Scanlan, J. Karbach, E. Jäger, A. Knuth, L. J. Old, and Y.-T. Chen Identification of a Tissue-specific Putative Transcription Factor in Breast Tissue by Serological Screening of a Breast Cancer Library Cancer Res., March 1, 2001; 61(5): 2055 - 2061. [Abstract] [Full Text]
|
|
|
|
|
|
R. T. Reilly, J.-P. H. Machiels, L. A. Emens, A. M. Ercolini, F. I. Okoye, R. Y. Lei, D. Weintraub, and E. M. Jaffee The Collaboration of Both Humoral and Cellular HER-2/neu-targeted Immune Responses Is Required for the Complete Eradication of HER-2/neu-expressing Tumors Cancer Res., February 1, 2001; 61(3): 880 - 883. [Abstract] [Full Text]
|
|
|
|
|
|
D. Monz, A. Munnia, N. Comtesse, U. Fischer, W.-I. Steudel, W. Feiden, B. Glass, and E. U. Meese Novel Tankyrase-related Gene Detected with Meningioma-specific Sera Clin. Cancer Res., January 1, 2001; 7(1): 113 - 119. [Abstract] [Full Text]
|
|
|
|
|
|
C. Meyer zum Buschenfelde, N. Nicklisch, S. Rose-John, C. Peschel, and H. Bernhard Generation of Tumor-Reactive CTL Against the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells Derived from CD34+ Hemopoietic Progenitor Cells J. Immunol., October 1, 2000; 165(7): 4133 - 4140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kobayashi, M. Wood, Y. Song, E. Appella, and E. Celis Defining Promiscuous MHC Class II Helper T-Cell Epitopes for the HER2/neu Tumor Antigen Cancer Res., September 1, 2000; 60(18): 5228 - 5236. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Gaiger, V. Reese, M. L. Disis, and M. A. Cheever Immunity to WT1 in the animal model and in patients with acute myeloid leukemia Blood, August 15, 2000; 96(4): 1480 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Reilly, M. B. C. Gottlieb, A. M. Ercolini, J.-P. H. Machiels, C. E. Kane, F. I. Okoye, W. J. Muller, K. H. Dixon, and E. M. Jaffee HER-2/neu Is a Tumor Rejection Target in Tolerized HER-2/neu Transgenic Mice Cancer Res., July 1, 2000; 60(13): 3569 - 3576. [Abstract] [Full Text]
|
|
|
|
|
|
V. Carr-Brendel, D. Markovic, K. Ferrer, M. Smith, J. Taylor-Papadimitriou, and E. P. Cohen Immunity to Murine Breast Cancer Cells Modified to Express MUC-1, a Human Breast Cancer Antigen, in Transgenic Mice Tolerant to Human MUC-1 Cancer Res., May 1, 2000; 60(9): 2435 - 2443. [Abstract] [Full Text]
|
|
|
|
|
|
D. Jager, E. Stockert, M. J. Scanlan, A. O. Gure, E. Jager, A. Knuth, L. J. Old, and Y.-T. Chen Cancer-Testis Antigens and ING1 Tumor Suppressor Gene Product Are Breast Cancer Antigens: Characterization of Tissue-specific ING1 Transcripts and a Homologue Gene Cancer Res., December 1, 1999; 59(24): 6197 - 6204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Comtesse, D. Heckel, A. Racz, N. Brass, B. Glass, and E. Meese Five Novel Immunogenic Antigens in Meningioma: Cloning, Expression Analysis, and Chromosomal Mapping Clin. Cancer Res., November 1, 1999; 5(11): 3560 - 3568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Yan, V. Vetvicka, Y. Xia, A. Coxon, M. C. Carroll, T. N. Mayadas, and G. D. Ross {beta}-Glucan, a ""Specific"" Biologic Response Modifier That Uses Antibodies to Target Tumors for Cytotoxic Recognition by Leukocyte Complement Receptor Type 3 (CD11b/CD18) J. Immunol., September 15, 1999; 163(6): 3045 - 3052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Disis, K. H. Grabstein, P. R. Sleath, and M. A. Cheever Generation of Immunity to the HER-2/neu Oncogenic Protein in Patients with Breast and Ovarian Cancer Using a Peptide-based Vaccine Clin. Cancer Res., June 1, 1999; 5(6): 1289 - 1297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Foon, J. Yannelli, and M. Bhattacharya-Chatterjee Colorectal Cancer as a Model for Immunotherapy Clin. Cancer Res., February 1, 1999; 5(2): 225 - 236. [Full Text] [PDF]
|
|
|
|
|
|
M. Ling, Y.-J. Wen, and S. H. Lim Prevalence of Antibodies Against Proteins Derived From Leukemia Cells in Patients With Chronic Myeloid Leukemia Blood, December 15, 1998; 92(12): 4764 - 4770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Guillaume, D. B. Rubinstein, and M. Symann Immune Reconstitution and Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation Blood, September 1, 1998; 92(5): 1471 - 1490. [Full Text] [PDF]
|
|
|
|
 |
|
 O. Tureci, U. Sahin, E. Vollmar, S. Siemer, E. Gottert, G. Seitz, A.-K. Parkkila, G. N. Shah, J. H. Grubb, M. Pfreundschuh, et al. Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers PNAS, June 23, 1998; 95(13): 7608 - 7613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Osanto Vaccine Trials for the Clinician: Prospects for Tumor Antigens Oncologist, October 1, 1997; 2(5): 284 - 299. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
